Effect of endothelin receptor antagonist bosentan on chronic hypoxia-induced inflammation and chemoafferent neuron adaptation in rat carotid body

High Alt Med Biol. 2012 Sep;13(3):209-16. doi: 10.1089/ham.2012.1011.

Abstract

Chronic hypoxia (CH) induces an inflammatory response in rat carotid body that is characterized by immune cell invasion and the expression of pro-inflammatory cytokines. In the present study, we have investigated the role of type-A endothelin (ET-A) receptors in the development of CH-induced inflammation. After 7 days of CH (380 Torr), double-label immunofluorescence studies demonstrated elevated levels of ET-A receptor and tyrosine hydroxylase (TH) in O(2)-sensitive type I cells. Following CH, ET-A receptors were also expressed on resident and invasive CD45+ immune cells distributed in tissue surrounding chemosensory cell lobules. Immnofluorescence and quantitative PCR studies showed that concurrent treatment with the ET-A/B receptor antagonist, bosentan (200 mg/kg/day), blocked CH-induced ED-1+ macrophage invasion and the upregulation of cytokines, including interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor α (TNFα), and monocyte chemoattractant protein-1 (MCP-1). Moreover, bosentan treatment blocked the CH-induced increases in expression of acid-sensitive ion channels (ASICs) in chemoafferent neurons in the petrosal ganglion (PG). Our findings are consistent with the hypothesis that CH-induced inflammation involves the upregulation and release of ET-1 from type I cells. ET-1 may act in an autocrine/paracrine mechanism via ET-A receptors on chemosensory type I cells and immune cells to promote an inflammatory response.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acid Sensing Ion Channels / drug effects
  • Adaptation, Physiological / drug effects
  • Animals
  • Antihypertensive Agents / pharmacology
  • Antihypertensive Agents / therapeutic use*
  • Bosentan
  • Carotid Body / immunology
  • Cell Movement / drug effects
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • Chemoreceptor Cells / drug effects
  • Chemoreceptor Cells / physiology*
  • Chronic Disease
  • Endothelin-1 / metabolism
  • Gene Expression / drug effects
  • Hypoxia / complications
  • Hypoxia / metabolism*
  • Inflammation / drug therapy*
  • Inflammation / etiology
  • Inflammation / metabolism*
  • Interleukin-1 / genetics
  • Interleukin-1 / metabolism
  • Interleukin-1beta / genetics
  • Interleukin-1beta / metabolism
  • Leukocyte Common Antigens / metabolism
  • Macrophages / drug effects
  • Rats
  • Receptor, Endothelin A / metabolism
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use*
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / metabolism
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Acid Sensing Ion Channels
  • Antihypertensive Agents
  • Chemokine CCL2
  • Endothelin-1
  • Interleukin-1
  • Interleukin-1beta
  • Receptor, Endothelin A
  • Sulfonamides
  • Tumor Necrosis Factor-alpha
  • Tyrosine 3-Monooxygenase
  • Leukocyte Common Antigens
  • Bosentan